gabapentin has been researched along with Cancer of Endometrium in 3 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We enrolled endometrial cancer patients undergoing open abdominal hysterectomy with lymphadenectomy by the same surgeon." | 1.40 | Multimodal pain control is associated with reduced hospital stay following open abdominal hysterectomy. ( Jennings, PW; Santoso, JT; Ulm, MA; Wan, JY, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Potter, B | 1 |
| Schrager, S | 1 |
| Dalby, J | 1 |
| Torell, E | 1 |
| Hampton, A | 1 |
| Santoso, JT | 1 |
| Ulm, MA | 1 |
| Jennings, PW | 1 |
| Wan, JY | 1 |
| Fleming, GF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial[NCT02922985] | Phase 4 | 120 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma[NCT03694262] | Phase 2 | 30 participants (Actual) | Interventional | 2019-07-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is the Apgar score of the newborn collected at 5 minutes. Range is from 0-10, with the higher scores meaning a better outcome. (NCT02922985)
Timeframe: 5 minutes after birth
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 9 |
| Multimodal Pain Regimen Group | 9 |
Time to discharge from hospital, measured in hours (NCT02922985)
Timeframe: From time of hospital admission to time of discharge home up to 168 hours.
| Intervention | hours (Median) |
|---|---|
| Placebo Control Group | 50.2 |
| Multimodal Pain Regimen Group | 50 |
neonate receipt of oxygen by nasal cannula or mechanical ventilation (NCT02922985)
Timeframe: after birth and before hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Control Group | 0 |
| Multimodal Pain Regimen Group | 4 |
Rate of admission to the neonatal intensive care unit (NCT02922985)
Timeframe: after birth and before hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Control Group | 2 |
| Multimodal Pain Regimen Group | 6 |
Number of opioid pain tablets remaining on post-operative day #7 from hospital discharge as reported by patients (NCT02922985)
Timeframe: 7 days post delivery
| Intervention | Tablets (Median) |
|---|---|
| Placebo Control Group | 18 |
| Multimodal Pain Regimen Group | 19 |
Pain Score at 24 Hours Post Operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 24 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 5 |
| Multimodal Pain Regimen Group | 6 |
Pain Score at 48 Hours Post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 48 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 4 |
| Multimodal Pain Regimen Group | 3 |
Pain score at 6-12 hours post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 6-12 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 6 |
| Multimodal Pain Regimen Group | 6 |
Time, in hours, to first administration of opioid pain medication post operatively (NCT02922985)
Timeframe: 48 hours post cesarean delivery
| Intervention | hours (Median) |
|---|---|
| Placebo Control Group | 6.05 |
| Multimodal Pain Regimen Group | 6.35 |
Every opioid intake by the patient in the first 48 hours after CD will be recorded and quantified in morphine milligram equivalents (NCT02922985)
Timeframe: 48 hours post cesarean delivery
| Intervention | morphine milligram equivalents (Median) |
|---|---|
| Placebo Control Group | 42 |
| Multimodal Pain Regimen Group | 49.5 |
2 reviews available for gabapentin and Cancer of Endometrium
| Article | Year |
|---|---|
Menopause.
Topics: Contraception; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Gabapentin; Hot Flashes; | 2018 |
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
Topics: Adenocarcinoma; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials | 2015 |
1 other study available for gabapentin and Cancer of Endometrium
| Article | Year |
|---|---|
Multimodal pain control is associated with reduced hospital stay following open abdominal hysterectomy.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Bupivacaine; Cohort S | 2014 |